[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@EiocOncology "Matterhorn associated with an os advantage Adding durva improves os across pdl1 subgroups #ESMO2025 #ESMO25 #CANCERRESEARCH #ONCOLOGY #YOUNGONCOLOGISTS #MATTERHIRN #ONCOLOGYCONFERENCE"
X Link @EiocOncology 2025-10-17T08:11Z XXX followers, XXX engagements

"👉out in the lancet 👉STELLAR-303 👉phase X trial 👉 improvement in overall survival zanzalintinibatezolizumab in patients with relapsed or refractory metastatic colorectal cancer that is not MSI-H or dMMR #ESMO25 #ESMO2025 #ONCOLOGYNEWS #ONCOLOGYRESEARCH #MEDICALCONFERENCE"
X Link @EiocOncology 2025-10-20T19:34Z XXX followers, XXX engagements

"Proud to welcome Bristol Myers Squibb as a Gold Sponsor at #EIOC2025 taking place XX Oct2 Nov 2025 at InterContinental Festival City Dubai United Arab Emirates. Complimentary registration for healthcare professionals: #Oncology #BMS #MedicalEducation"
X Link @EiocOncology 2025-10-17T07:12Z XXX followers, XX engagements

"Sara Hurwitz presents results of Vitoria X. Lessons learnt: X. Combination therapy matters in the hr pos disease X. there is a role for cdk4/6i beyond progression of disease #ESMO25 #ESMO2025 #ONCOLOGYNEWS @OncoAlert #ONCOLOGYRESEARCH #MEDICALCONFERENCE #ONCOALERT #ASCO #EIOC"
X Link @EiocOncology 2025-10-18T11:07Z XXX followers, XXX engagements

"(1/2) 👉DYNAMIC-III trial 👉ctDNA-guided adjuvant CTx de-escalation in stage III CRC 👉analysis of the ctDNA-cohort 👉 reduced oxaliplatin exposure 👉 non-inferiority not demonstrated"
X Link @EiocOncology 2025-10-20T18:37Z XXX followers, XX engagements

"Join us on X Nov 2025 at EIOC 2025 as Dr. Ammar Madani from NCCCR Kuwait discusses Evolution of Checkpoint Inhibitors in rNSCLC. 🔗 #EIOC2025 #LungCancer #NSCLC #Immunotherapy"
X Link @EiocOncology 2025-10-22T13:25Z XXX followers, XX engagements